Sutro Biopharma, Inc. — Q1 2020 Form 10-Q
Business context and period. Clinical-stage drug discovery, development and manufacturing company using its XpressCF platform, focused on cancer and autoimmune therapeutics. This unaudited report covers the three months ended March 31, 2020, compared with Q1 2019. Sutro had no products approved for commercial sale; revenue came from collaborations, supply and services.
Financial results and liquidity
| Metric | Q1 2020 / March 31, 2020 | Q1 2019 / comparator |
|---|---|---|
| Revenue | $7.2 million | $8.6 million; down 17% |
| Research and development expense | $17.6 million | $15.2 million; up 16% |
| General and administrative expense | $8.7 million | $7.7 million; up 13% |
| Operating loss | $19.2 million | $14.3 million |
| Net loss / loss per share | $19.6 million / $0.84 | $14.3 million / $0.62 |
| Cash used in operating activities | $18.7 million | $20.1 million |
| Cash, cash equivalents and marketable securities | $129.6 million | $133.5 million at December 31, 2019 |
| Debt | $24.2 million carrying value; $25.0 million principal under new loan | $9.9 million carrying value at December 31, 2019 |
Cash and marketable securities totaled approximately $129.6 million at quarter-end; current liabilities were $32.0 million and total liabilities $71.8 million. Stockholders’ equity was $82.1 million, versus $97.8 million at year-end 2019. No product margins are reported because the company had no commercial product sales.
Changes versus the prior period
- Revenue fell $1.5 million, principally reflecting lower Merck collaboration revenue. BMS revenue increased $0.5 million, EMD Serono revenue increased $0.2 million, and SutroVax revenue decreased $0.2 million.
- Operating expenses rose $3.4 million, driven by higher personnel costs and consulting and outside services. Net loss increased $5.3 million.
- Q1 operating cash outflow improved by $1.4 million year over year. Cash increased $38.6 million during the quarter, mainly from marketable-security maturities and sales and the debt refinancing—not from operating cash generation.
- In February 2020, Sutro refinanced its prior loan, borrowing $25.0 million and using approximately $9.6 million to repay the former facility. The new loan matures March 1, 2024, carries a floating rate with an 8.07% floor, and is interest-only through March 1, 2022. It is secured by company assets other than intellectual property and includes restrictive covenants.
Outlook, commentary and risks
- Management said quarter-end cash, cash equivalents and marketable securities were expected to fund operations for at least 12 months from the financial statements’ issuance date. The company expects substantial future losses and says additional capital will be needed; no specific full-year financial guidance is provided.
- Revenue includes a material Merck accounting estimate adjustment: reallocating resources between two research programs reduced Q1 revenue by $5.1 million and increased net loss by the same amount. Separately, Merck’s $5.0 million payment to extend a program’s research term increased the transaction price; Sutro recorded a $2.0 million cumulative catch-up in revenue. The payment was received in April 2020.
- STRO-001 and STRO-002 were in Phase 1 trials. Updated STRO-002 interim data announced April 27, 2020 included one ongoing confirmed partial response and stable disease in some patients at higher doses. The company emphasized that stable disease is not an FDA-defined objective response. It planned further safety and initial efficacy data and dose expansion in the second half of 2020.
- COVID-19 effects were uncertain as of filing. Potential impacts included clinical-trial enrollment and site delays, supply-chain and manufacturing disruptions, and delays in regulatory review. The company had changed workplace practices and restricted on-site staff to prioritized activities.
- Key risks include clinical and regulatory failure, reliance on collaboration partners and third-party suppliers, manufacturing scale-up and compliance, need for additional financing, dilution, and debt covenants. The filing reports no material pending legal proceeding and no off-balance-sheet arrangements.
Important facts for investors to verify
- How the Merck resource reallocation and transaction-price catch-up affect reported revenue, deferred revenue and future recognition.
- Whether the stated cash runway remains realistic given quarterly operating cash use, planned clinical and manufacturing spending, and the need for additional capital.
- Subsequent STRO-002 trial updates, including response durability, safety, dose selection and the distinction between stable disease and objective responses.
- Any COVID-19-related changes to trial enrollment, timelines, manufacturing or supply, and any updates to management’s assessment of these effects.
- Debt terms, covenant compliance and potential dilution from outstanding equity awards and warrants; the filing reported 23.2 million common shares outstanding at March 31, 2020.
- Whether BMS collaboration-program rights change: the filing notes that ex-U.S. rights to three programs could revert if specified milestones were not achieved by September 26, 2020.